Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 108Brain Neoplasms 106Glioma 83Neuroblastoma 34Astrocytoma 26Neoplasms 25Medulloblastoma 25Central Nervous System Neoplasms 25Neurofibromatosis 1 23Meningioma 23Ependymoma 22Sarcoma 21Breast Neoplasms 18Rhabdoid Tumor 16Melanoma 16Neurofibroma, Plexiform 15Carcinoma, Non-Small-Cell Lung 15Osteosarcoma 14Wilms Tumor 13Rhabdomyosarcoma 13Thyroid Neoplasms 12Sarcoma, Ewing 12Hepatoblastoma 12Gliosarcoma 12Recurrence 11Diffuse Intrinsic Pontine Glioma 11Pheochromocytoma 10Pancreatic Neoplasms 10Neoplasm Metastasis 10Ovarian Neoplasms 9

Interventions

ulixertinib 1tipifarnib 1tazemetostat 1selpercatinib 1palbociclib 1olaparib 1larotrectinib 1ivosidenib 1erdafitinib 1ensartinib 1X-Rays 1Vemurafenib 1Specimen Handling 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Magnetic Resonance Spectroscopy 1LY3023414 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xanthogranuloma, Juvenile × CNS × 30 days × Clear all
NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡